Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Provided By GlobeNewswire
Last update: Mar 27, 2024
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial
- Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025
